A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 19-22

  Marcus, R ^a   Aultman, R ^b   Jost, F ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cyclophosphamide, vincristine, and prednisone; Follicular lymphoma; Health related quality of life; Quality adjusted survival; Quality adjusted time without disease symptoms or toxicities of treatment; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MULTICENTER STUDIES AS TOPIC; PREDNISONE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 74249084471     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605443     Document Type: Article

References (13)

1. Cole BF, Solal-Celigny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A (1998) Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 16: 2339-2344
2. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8: 723-731
3. Fayers PM, Machin D (2000) Quality of Life. Assessment, Analysis and Interpretation. Wiley: Chichester, pp xii+404. ISBN 0-471-96861-7
4. Fine JP, Gelber RD (2001) Joint regression analysis of survival and quality-adjusted survival. Biometrics 57: 376-382
5. Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20: 75-88
6. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417-1423
7. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26: 4579-4586
8. Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D (2008) The impact of follicular lymphoma on health-related quality of life. Ann Oncol 19: 570-576
9. Revicki DA, Feeny D, Hunt TL, Cole BF (2006) Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 15: 411-423
10. Staquet MJ, Hays RD, Fayers PM (eds) (1998) Using the Q-TWiST Method for Treatment Comparisons in Clinical Trials. Oxford University Press: USA, pp 281-296
11. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909-3918
12. Vose D (2000) Risk Analysis-A Quantitative Guide 2nd edn, John Wiley & Sons: Chichester
13. Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J (1998) Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 16:2834-2839